Dr. Filtz's general research interest is in how a cell receives a signal and then transmits that signal to alter its function in response. She is more particularly interested in how signaling proteins are regulated to change their activity. In collaboration with Dr. Mark Leid in the College of Pharmacy at OSU, Dr. Filtz is studying regulation of a tumor suppressor protein, Bcl11b. Bcl11b is critical for the proper development of T cells in the immune system; loss of Bcl11b is associated with T cell leukemias. The Filtz and Leid labs are seeking to define the molecular alterations of BCL11B that affect its function, potentially providing hints for new drug targets. Another project in Dr. Filtz’s lab started with work conducted in the laboratory of Dr. Elizabeth Woodcock in Melbourne Australia. In this project, Dr. Filtz is exploring alterations in levels of phospholipase C-beta, a ubiquitous signaling enzyme, in the development of a common heart arrhythmia, atrial fibrillation. For this project, Dr. Filtz is currently collaborating with Dr. Chrissa Kioussi in the College of Pharmacy at OSU. Dr. Kioussi has a mutant mouse model of congenital heart defects that, among other problems, is prone to the development of atrial fibrillation. Additionally, Dr. Filtz has been involved in screening natural product compounds for direct activity on heart cells. She has shown that two different plant products, an herbal extract of hawthorn tree, and the chemical berberine from various plant sources including Oregon grape, have direct activity on heart cells through classic receptor subtypes.
College of PharmacyOregon State UniversityCorvallis, OR 97331Phone: 541.737.3424Fax: 541.737.3999